Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.

ABSTRACT: Current guidelines recommend behavioral treatment (BT) as the first intervention for patients with obesity. However, a substantial minority (35-50%) do not achieve a clinically meaningful loss of ≥5%. Anti-obesity medications (AOMs) are recommended when target weight loss is not achieved; however, their efficacy among BT nonresponders has not been established. This double-blind, randomized controlled proof-of-principle study evaluated whether augmenting BT with AOM improved 24-week weight loss compared to BT with placebo in early nonresponders to BT. A total of 147 adults with a body mass index ≥31 kg m^-2 (≥28 kg m^-2 with obesity-related comorbidity) completed an initial 4-week BT run-in. The 76 early nonresponders who lost <2.0% of initial weight were then randomized

SUBMITTER: Tronieri JS 

PROVIDER: S-EPMC12092266 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature